S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.81 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.00 (-2.29%)
NIO   7.75 (+4.31%)
BABA   71.49 (-1.23%)
AMD   116.82 (-1.32%)
T   16.94 (-1.63%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.79 (-1.03%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.81 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.00 (-2.29%)
NIO   7.75 (+4.31%)
BABA   71.49 (-1.23%)
AMD   116.82 (-1.32%)
T   16.94 (-1.63%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.79 (-1.03%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.81 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.00 (-2.29%)
NIO   7.75 (+4.31%)
BABA   71.49 (-1.23%)
AMD   116.82 (-1.32%)
T   16.94 (-1.63%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.79 (-1.03%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.81 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.00 (-2.29%)
NIO   7.75 (+4.31%)
BABA   71.49 (-1.23%)
AMD   116.82 (-1.32%)
T   16.94 (-1.63%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.79 (-1.03%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)

Biohaven Stock Price, News & Analysis (NYSE:BHVN)

$33.32
-0.18 (-0.54%)
(As of 04:00 PM ET)
Compare
Today's Range
$32.96
$34.15
50-Day Range
$22.96
$33.96
52-Week Range
$12.35
$34.21
Volume
672,334 shs
Average Volume
1.05 million shs
Market Capitalization
$2.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.17

Biohaven MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
12.3% Downside
$29.17 Price Target
Short Interest
Healthy
10.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.09mentions of Biohaven in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$3.40 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($5.23) to ($5.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

788th out of 949 stocks

Pharmaceutical Preparations Industry

348th out of 408 stocks


BHVN stock logo

About Biohaven Stock (NYSE:BHVN)

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

BHVN Stock Price History

BHVN Stock News Headlines

Biohaven (NYSE:BHVN) Trading Down 2.6%
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Biohaven Independent Director Acquires 8.0% More Stock
Biohaven Ltd. (BHVN) Gets a Buy from Piper Sandler
Biohaven proposes $200M stock offering
See More Headlines
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
928
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.17
High Stock Price Target
$36.00
Low Stock Price Target
$24.00
Potential Upside/Downside
-12.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-570,280,000.00
Pretax Margin
-255.54%

Debt

Sales & Book Value

Annual Sales
$462.51 million
Book Value
$7.90 per share

Miscellaneous

Free Float
67,798,000
Market Cap
$2.69 billion
Optionable
Optionable
Beta
1.03
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














BHVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Biohaven stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings
or view top-rated stocks.

What is Biohaven's stock price target for 2024?

5 analysts have issued 12-month price targets for Biohaven's stock. Their BHVN share price targets range from $24.00 to $36.00. On average, they expect the company's stock price to reach $29.17 in the next twelve months. This suggests that the stock has a possible downside of 12.3%.
View analysts price targets for BHVN
or view top-rated stocks among Wall Street analysts.

How have BHVN shares performed in 2023?

Biohaven's stock was trading at $13.88 at the beginning of 2023. Since then, BHVN stock has increased by 139.6% and is now trading at $33.25.
View the best growth stocks for 2023 here
.

Are investors shorting Biohaven?

Biohaven saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 6,180,000 shares, a decrease of 8.0% from the October 31st total of 6,720,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 5.3 days. Approximately 10.5% of the company's shares are sold short.
View Biohaven's Short Interest
.

When is Biohaven's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our BHVN earnings forecast
.

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) announced its earnings results on Tuesday, November, 14th. The company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of ($1.33) by $0.17.

What ETFs hold Biohaven's stock?

ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven IPO?

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Who are Biohaven's major shareholders?

Biohaven's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (8.44%), FMR LLC (4.77%), Armistice Capital LLC (2.98%), Avidity Partners Management LP (1.88%), Adage Capital Partners GP L.L.C. (1.82%) and Northern Trust Corp (0.81%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John W Childs, Julia P Gregory, Matthew Buten and Vlad Coric.
View institutional ownership trends
.

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:BHVN) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -